Diverticulitis is the acute inflammation of the diverticulum or saclike protrusion from the wall of the intestines caused by injury and bacterial proliferation.
Abdominal pain is usually localized to the left lower quadrant, is abrupt, steady, severe and worsens over time.
Other signs and symptoms are fever, anorexia, nausea, vomiting, and altered bowel movements especially constipation but may also present with diarrhea or tenesmus.
Noninclusion of antibiotics in the management of uncomplicated acute diverticulitis is feasible and fairly safe, with long-term follow-up data from the DIABOLO study showing that such a strategy does not result in increased incidence of complicated or recurrent diverticulitis or sigmoid resections over 2 years.
A strong belief in the necessity of medication is associated with better adherence to oral disease-modifying antirheumatic drugs (DMARDs) or prednisone, while higher self-efficacy correlates with poor adherence, in a diverse cohort of patients with rheumatoid arthritis (RA), suggests a study.
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Percutaneous coronary intervention (PCI) displays comparable rates of mortality and serious composite outcomes but a higher rate of target-vessel revascularization at 10 years relative to coronary artery bypass grafting (CABG) in patients with significant left main coronary artery (LMCA) disease, reports a study. On the other hand, CABG delivers lower mortality and serious composite outcome rates compared with PCI with drug-eluting stents after 5 years.